Nevro Corp NVRO
We take great care to ensure that the data presented and summarized in this overview for NEVRO CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NVRO
View all-
Arrow Mark Colorado Holdings LLC Denver, CO4.36MShares$25 Million0.24% of portfolio
-
Armistice Capital, LLC New York, NY3.74MShares$21.4 Million0.2% of portfolio
-
Black Rock Inc. New York, NY3.6MShares$20.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.06MShares$11.8 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY1.8MShares$10.3 Million0.01% of portfolio
-
Braidwell LP Stamford, CT1.7MShares$9.73 Million0.35% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD1.65MShares$9.44 Million0.24% of portfolio
-
Shay Capital LLC New York, NY1.08MShares$6.21 Million0.66% of portfolio
-
Morgan Stanley New York, NY1.04MShares$5.96 Million0.0% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL932KShares$5.34 Million0.0% of portfolio
Latest Institutional Activity in NVRO
Top Purchases
Top Sells
About NVRO
Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. It also provides 10 kHz Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was incorporated in 2006 and is headquartered in Redwood City, California.
Insider Transactions at NVRO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 24
2025
|
Kevin R Thornal President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,685
-2.68%
|
$33,425
$5.16 P/Share
|
|
Jan 04
2025
|
Kashif Rashid SVP, Corp Dev and CLO |
SELL
Payment of exercise price or tax liability
|
Direct |
527
-0.33%
|
$1,581
$3.71 P/Share
|
|
Dec 31
2024
|
Elizabeth H Weatherman Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,325
+5.82%
|
-
|
|
Dec 31
2024
|
Sridhar Kosaraju Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,233
+8.33%
|
-
|
|
Dec 31
2024
|
Michael F Demane Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,056
+10.24%
|
-
|
|
Dec 19
2024
|
Greg Siller SVP & Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,072
-2.11%
|
$9,216
$3.59 P/Share
|
|
Dec 07
2024
|
Christofer Christoforou SVP, Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,319
-0.95%
|
$5,276
$4.19 P/Share
|
|
Dec 07
2024
|
Kashif Rashid SVP, Corp Dev and CLO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,759
-1.1%
|
$7,036
$4.19 P/Share
|
|
Dec 07
2024
|
Roderick H. Mac Leod SVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,759
-1.32%
|
$7,036
$4.19 P/Share
|
|
Dec 03
2024
|
D Keith Grossman Director |
SELL
Payment of exercise price or tax liability
|
Direct |
928
-0.41%
|
$3,712
$4.26 P/Share
|
|
Nov 28
2024
|
Kashif Rashid SVP, Corp Dev and CLO |
SELL
Payment of exercise price or tax liability
|
Direct |
816
-0.51%
|
$3,264
$4.58 P/Share
|
|
Nov 28
2024
|
Christofer Christoforou SVP, Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
583
-0.42%
|
$2,332
$4.58 P/Share
|
|
Nov 28
2024
|
Roderick H. Mac Leod SVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
816
-0.61%
|
$3,264
$4.58 P/Share
|
|
Oct 24
2024
|
Kevin R Thornal President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,063
-2.37%
|
$24,252
$4.85 P/Share
|
|
Oct 04
2024
|
Kashif Rashid SVP, Corp Dev and CLO |
SELL
Payment of exercise price or tax liability
|
Direct |
479
-0.3%
|
$1,916
$4.97 P/Share
|
|
Sep 30
2024
|
Michael F Demane Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,695
+7.89%
|
-
|
|
Sep 30
2024
|
Sridhar Kosaraju Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,817
+6.24%
|
-
|
|
Sep 30
2024
|
Elizabeth H Weatherman Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,544
+4.2%
|
-
|
|
Sep 19
2024
|
Greg Siller SVP & Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,070
-2.07%
|
$15,350
$5.85 P/Share
|
|
Sep 07
2024
|
Kashif Rashid SVP, Corp Dev and CLO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,759
-1.08%
|
$8,795
$5.18 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 612K shares |
|---|
| Bona fide gift | 6.75K shares |
|---|---|
| Payment of exercise price or tax liability | 122K shares |